Medulloblastoma (MB) is the most common malignant brain
cancer in children. Children diagnosed with the disease undergo intense
therapy, including surgery, radiation, and high-dose chemotherapy. Although
current treatment regimens have improved 5-year survival rates, almost a third
of MB patients still die from their disease, and children who survive suffer
long-term side effects that affect their quality of life.